+Compare
SCLX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
244.45M

SCLX Scilex Holding Company Forecast, Technical & Fundamental Analysis

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for SCLX with price predictions
08:00 PM EDT Sep 26, 2023

SCLX's Indicator enters downward trend

The Aroon Indicator for SCLX entered a downward trend on September 27, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 35 similar instances where the Aroon Indicator formed such a pattern. In of the 35 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for SCLX just turned positive on September 27, 2023. Looking at past instances where SCLX's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SCLX advanced for three days, in of 80 cases, the price rose further within the following month. The odds of a continued upward trend are .

SCLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SCLX's P/B Ratio (22.173) is slightly higher than the industry average of (6.190). SCLX has a moderately low P/E Ratio (0.000) as compared to the industry average of (31.876). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.319). SCLX's Dividend Yield (0.000) is considerably lower than the industry average of (0.028). P/S Ratio (4.960) is also within normal values, averaging (3.732).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SCLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 67, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 80.42B. The market cap for tickers in the group ranges from 72.83K to 524.29B. LLY holds the highest valuation in this group at 524.29B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -3%. MIRA experienced the highest price growth at 11%, while OGN experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 20%. For the same stocks of the Industry, the average monthly volume growth was 33% and the average quarterly volume growth was 4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 28
P/E Growth Rating: 60
Price Growth Rating: 57
SMR Rating: 57
Profit Risk Rating: 66
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
960 San Antonio Road
Phone
+1 650 516-4310
Employees
90
Web
https://www.scilexholding.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PQCCX9.560.06
+0.63%
PGIM Quant Solutions Mid-Cap Cor Eq R6
GSRRX10.720.02
+0.19%
Goldman Sachs Rising Dividend Gr R
TGIHX14.460.01
+0.07%
TIAA-CREF Growth & Income Advisor
GSTRX7.32N/A
N/A
Goldman Sachs Strategic Growth R
FNGZX13.94-0.05
-0.36%
Franklin Intl Growth Adv

SCLX and

Correlation & Price change

A.I.dvisor tells us that SCLX and OGN have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCLX and OGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCLX
1D Price
Change %
SCLX100%
-0.64%
OGN - SCLX
9%
Poorly correlated
-3.83%
GRFS - SCLX
9%
Poorly correlated
-0.76%
AZN - SCLX
5%
Poorly correlated
-0.41%
PFE - SCLX
5%
Poorly correlated
-0.93%
JNJ - SCLX
1%
Poorly correlated
-1.20%
More

Groups containing SCLX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCLX
1D Price
Change %
SCLX100%
-0.64%
Pharmaceuticals
(undefined stocks)
7%
Poorly correlated
+23.35%
Pharmaceuticals: Major
(undefined stocks)
4%
Poorly correlated
+0.22%